Copy to clipboard 
Contrary to common perception, the relationship between orthopedic startups and large established companies rarely begins with an acquisition offer. It begins much earlier — in distribution agreements, manufacturing partnerships and co-development arrangements. Understanding this interdependence is essential for anyone navigating the orthopedic innovation landscape.
Sales Channel as a Structural Moat
Distribution is one of the most powerful structural barriers in orthopedics. Relationships between surgeons, hospitals and sales representatives are built over many years deeply embedded in O.R. workflows. For a startup, even a highly innovative technology can struggle to penetrate the market without access to established sales channels.
This is why distribution partnerships between startups and established companies are so common. Large orthopedic firms have invested decades in building their commercial infrastructure. Startups bring innovation that can refresh these portfolios, while the strategic partner provides the channel required to scale adoption. Neither side holds all the cards.
Distribution partnerships are not a shortcut. They are a structural necessity for most orthopedic startups and a strategic opportunity for the established companies willing to engage early.
The ‘Platformization’ of Medtech Supply
Manufacturing represents a second critical partnership layer. The medtech contract manufacturing sector has increasingly become “platformized.” CDMOs now provide scalable quality systems and integrated capabilities that cover design transfer, validation pathways and production at scale.
Private equity has simultaneously invested heavily in building manufacturing platforms across adjacent orthopedic segments. For startups, the practical benefits are significant: access to established ISO quality systems without building them from scratch, scalable production capacity without heavy upfront capital expenditure and credible design transfer and validation pathways that strengthen due diligence positioning.
For strategic acquirers, this same consolidation also reduces integration risk. Standardized quality systems and scalable suppliers simplify the post-acquisition transition, which in turn can accelerate deal timelines.
Why Strategics Often Acquire Rather Than Build
In orthopedics, the decision to acquire rather than build internally is not simply a strategic preference. It is often the most practical path from both a financial and an organizational perspective. Several factors drive this dynamic.
- Accounting dynamics. Internal R&D spending flows directly through the income statement, reducing operating profit. Acquisitions behave differently. The purchase price is recorded on the balance sheet as goodwill or intangible assets, and many companies report adjusted earnings metrics that exclude related amortization. The result is that acquisitions can have limited impact on adjusted earnings per share (EPS), while internal R&D directly reduces reported earnings.
- Organizational dynamics. Large organizations face significant internal hurdles when pursuing disruptive innovation. Major R&D programs require budget allocation, cross-functional alignment and executive sponsorship. Where the probability of success is uncertain, internal development often gravitates toward incremental innovation within existing portfolios.
- Political capital. Radical innovation inside large organizations frequently requires significant internal political support. Without strong executive backing, disruptive programs can struggle to survive internal scrutiny, particularly where they challenge established product lines or commercial models.
- Startup speed. Startups operate under a fundamentally different set of incentives. Smaller companies are primarily focused on solving a specific technical problem and reaching product market fit. They are less constrained by internal structures and quarterly earnings pressures.
The result is a natural division of labor. Startups explore higher-risk innovation and validate clinical adoption. Strategics integrate technologies once adoption signals become clear. This is not a dysfunction — it is how the category is designed to work.
Creating Strategic Value
If strategics increasingly rely on startups to deliver step-change innovation, the question becomes: what exactly do the most successful orthopedic startups build that makes them strategically valuable? The answer goes well beyond the product itself.
Internal development programs at large companies must clear high hurdle rates. Portfolio cannibalization creates organizational resistance. Field force change management is expensive. Speed to market matters in competitive procedural categories. For all these reasons, strategics frequently allow startups to absorb the earliest stages of risk: generating first clinical evidence, proving surgeon adoption and validating workflow advantages.
Once behavioral traction is visible, capital follows. The most successful orthopedic startups understand this dynamic early and build companies that are not only innovative but also integration ready.
The Assets That Matter
Successful orthopedic startups tend to build a specific constellation of assets that compound their strategic value over time.
- Product market fit. Repeat use, reproducibility and workflow advantages that surgeons actively value and return to.
- Differentiated intellectual property. Focused IP around a specific unmet need, reinforced through manufacturing processes, design features and clinical integration rather than broad patent coverage alone.
- Surgeon networks. Early adopters serve not only as users but as validators and diffusers of trust across the orthopedic community. These networks are not easily replicated after acquisition.
- Strategic partnerships. Upstream relationships with suppliers and manufacturers, combined with downstream collaborations with distributors and strategic partners, that validate commercial capability.
- Scalable margin architecture. Thoughtful supply chain design and disciplined cost management that preserves both operational independence and strategic attractiveness to acquirers.
- Narrative clarity. Alignment between product development, clinical evidence and commercial strategy around a single coherent story that reduces diligence friction.
- Capital efficiency. Investment capital deployed against early risk absorption, creating assets that can scale within larger organizations rather than simply burning through funding.
Integration readiness often determines long-term strategic value more than the technology itself. The most acquirable startups are those that have anticipated what a strategic partner will need to scale them.
Opportunities Across the Ecosystem
Orthopedics is entering a period of sharper portfolio choices by strategics and deeper participation by private equity across services, manufacturing and potentially large platform assets. In this environment, the interdependence between startups, strategics and contract manufacturers becomes more important, not less.
For startups, the priority is clear: find real product market fit in the operating room, cultivate the partnerships that enable scaling and feed the innovation pipeline that larger organizations depend on.
For strategics and contract manufacturers, the opportunity is equally clear: enable slick integration by offering transparency around QMS requirements, validation pathways and testing standards. Maintain alignment with innovators while creating the conditions for startups to continue adding value independently.
The orthopedic innovation system is not a competition between startups and large companies. It is a partnership between organizations optimized for different stages of innovation.
Startups explore new concepts and validate early clinical adoption. Established companies bring the global infrastructure required to scale technologies safely and reliably; regulatory expertise, manufacturing capacity, distribution networks and surgeon education platforms that remain essential for translating innovation into standard clinical practice.
The next phase of orthopedic growth may not be defined by who invents the most technologies. It may be defined by who integrates innovation most effectively — and by startups that design from the beginning with integration, capital efficiency and clinical reproducibility in mind.
Editor’s Note: The first installment of this two-part series examines why startups are not peripheral to orthopedics. They are a structural mechanism through which the category renews itself, pipelines innovation and adapts to shifts in capital markets, care models and manufacturing capacity.
Maxwell Munford, Ph.D., is Founder and CEO of OSSTEC, a medtech company developing next-generation orthopedic implants built on deep technical expertise from Imperial College London. Secure your spot at OMTEC 2026 to hear Munford speak about turning supplier relationships into strategic partnerships.
Dan Pryor is an experienced industrial and medical technology executive and board director. He previously served as Executive Vice President at Enovis, where he helped lead its transformation into a global medical technology platform through more than 50 acquisitions and divestitures representing over $14 billion in enterprise value.
